pre - feasibility reportenvironmentclearance.nic.in/writereaddata/formb/tor/… · ·...
TRANSCRIPT
PRE - FEASIBILITY REPORT
For Proposed Active Pharma Ingredient
Manufacturing Unit
at
C-1/511, Kerala GIDC Estate, At-Kerala,
Ta-Bavla, Ahmedabad
By
SHREE HARIKRISHNA PHARMACEUTICALS
Prepared by:
En-vision Enviro Technologies Pvt. Ltd.
2nd
Floor, Shree Ram Complex, Above Bank of India,
Near Kargil Chowk, Surat Dumas Road, Piplod, Surat-395007, Gujarat, India
Contact No: +91 2612223003, 2224004
E-mail: [email protected]; Website: www.en-vision.in
January – 2018
INDEX
CHAPTER-1 INTDOUCTION OF THE PROJECT ............................................................................. 1
CHAPTER-2 PROJECT DESCRIPTION .............................................................................................. 3
CHAPTER-3 SITE ANALYSIS ............................................................................................................... 8
CHAPTER-4 PLANNING BRIEF ......................................................................................................... 10
CHAPTER-5 PROPOSED INFRASTRUCTURE ................................................................................ 12
CHAPTER-6 REHABILITATION AND RESETTLEMENT (R & R) PLAN .................................. 13
CHAPTER-7 PROJECT SCHEDULE & COST ESTIMATES .......................................................... 14
CHAPTER-8 ANALYSIS OF PROPOSAL .......................................................................................... 15
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
1
CHAPTER-1 INTDOUCTION OF THE PROJECT
1.1 IDENTIFICATION OF PROJECT AND PROJECT PROPONENT
M/s. Shree Harikrishna Pharmaceuticals is planning set up the API manufacturing unit at C-1/511, Kerala
GIDC area, At-Kerala, Taluka Bavla, Ahmedabad.
Table 1-1: Proposed Product and Capacity
Sr.
No Product name
Capacity
(MTPM)
1 Deflazacort
10
2 Acebrophylline
3 Thiocolchicoside
4 Solifenacin Succinate
5 Anagliptin
6 Atazanavir sulphate
7 Esclicarbazepine Acetate
8 Febuxostat
9 Flupirtine maleate
10 Methyl cobalamine
11 Mirabegron
12 Pidotimod
13 Teneligliptin Hydrobromide Hydrate
14 Valsartan
15 Pirfenidone
16 N-Boc Amino acid
17 Fluconazole
18 Lostaran Potassium
19 Clopidogril Sulphate
20 Sertraline HCl
21 Oxcarbazepine
22 Nebivolol
23 Telmisartan
24 Clomipramine HCl
25 Bisoprolol Fumarate
26 Tadalafil
27 Ticagrelor 0.1
28 Vardenafil Hydrochloride Trihydrate 0.2
29 Atorvastatin Calcium 0.2
30 Rosuvastatin Calcium 0.1
The proposed products fall under Category 5(f) as stated in Environment Impact Assessment Notification
Published on 14th September, 2006. The unit is located in notified area of GIDC Kerala hence the project
proponent has to obtain the EC from the SEIAA, Gujarat.
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
2
The pharmaceutical industry is based primarily upon the scientific research and development (R&D) of
medicines that prevent or treat disease and disorder. Modern scientific and technology advances are accelerating
the discovery and development of innovative pharmaceuticals with improved therapeutic activity and reduced
side effects. Industrial chemicals are used in researching and developing active drug substances and
manufacturing bulk substances and finished pharmaceutical products. M/s. En-vision Enviro Technologies
Private Limited has been appointed to carry out EIA/EMP studies for Environmental Clearance.
Total plot area of the site is 703 m2 out of which 232 m
2 (33% of total land area) will
be developed as greenbelt.
The estimated project cost is 2.5 Crores. Total budget allocation towards Environmental Management Facilities
will be Rs. 50 lacs. Total 15 personnel will be required; including skilled persons, unskilled persons and office
staff.
1.2 PROMOTERS BACKGROUND
Dr. Kalpeshbhai Menpara, about age: 34 years, M.Sc. (Org. Chemistry) Ph.D.(Organic chemistry)
having 11 years experience in R. & D. department of pharmaceutical industry.
1.3 BRIEF DESCRIPTION OF NATURE OF THE PROJECT
The proposed unit is a small scale project for production of Bulk Drugs & Bulk Drug Intermediates
manufacturing.
1.3.1 Need for the Project and Its Importance to the Country and/or Region
The proposed project will provide a potential & required growth opportunity for the Company. Moreover
company has strong presence with leading pharma customers locally as-well-as internationally; mainly in
regulated market. The company & the products are well approved & registered with the leading regulatory
authorities & the pharma customers’ in local & international markets.
The Active Pharmaceutical Ingredient Industry is the organ by which active pharmaceutical ingredients are
manufactured from raw materials through both chemical and physical means. Depending on the complexity of
the molecule required, synthesis of APIs might need multi-step complex chemistry utilizing a range of
processing technologies.
1.3.2 Demand-Supply Gap
The pharma / health industrial sector in the past many years has seen a consistent growth and also keeping in
mind our strong presence in the local & global market. Hence we have identified the demand for the proposed
products which are meant for very new medicines meant for fast growing therapeutic segments with pilot plant
developed our own process patents we can take a lead & produce commercially in bulk for domestic market as
well as with strong presence in export markets.
1.3.3 Employment Generation (Direct and Indirect)
Total 15 personnel will be employed during operation phase.
PRE-FEASIBILITY REPORT OF PROPOSE
CHAPTER-2 PROJECT DESCRIPTION
2.1 TYPE OF PROJECT INCL
PROJECTS
Industrial development in India has increased economic growth and improved living standards of people. These
growths are achieved through industrialization, infr
major role in development of the country. This industrialization is also has many other benefits. Although the
industrial development leads to rapid consumption of natural resources, fuel etc.
activity. To control the pollutions from industrial activity, government has framed regulations which are
governed by Ministry of Environment, Forests and Climate Change in India.
2.2 LOCATION
M/s. Shree Harikrishna Pharmaceuticals
Ta-Bavla, Ahmedabad. Total plot area of the site is 703 m2 from which 232 m2 will be developed as greenbelt,
thus 33% of total land area will be covered with green belt.
EPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
PROJECT DESCRIPTION
TYPE OF PROJECT INCLUDING INTERLINKED AND INTERDEPENDENT
Industrial development in India has increased economic growth and improved living standards of people. These
growths are achieved through industrialization, infrastructure development. The industrialization has played a
major role in development of the country. This industrialization is also has many other benefits. Although the
industrial development leads to rapid consumption of natural resources, fuel etc. in day to day operational
To control the pollutions from industrial activity, government has framed regulations which are
governed by Ministry of Environment, Forests and Climate Change in India.
M/s. Shree Harikrishna Pharmaceuticals is planning to set up plant at C-1/511, Kerala GIDC Estate, At
Total plot area of the site is 703 m2 from which 232 m2 will be developed as greenbelt,
thus 33% of total land area will be covered with green belt. A map showing project site is given in
Identification
1
2
3
4
HARMACEUTICALS
3
D INTERDEPENDENT
Industrial development in India has increased economic growth and improved living standards of people. These
astructure development. The industrialization has played a
major role in development of the country. This industrialization is also has many other benefits. Although the
ay to day operational
To control the pollutions from industrial activity, government has framed regulations which are
1/511, Kerala GIDC Estate, At-Kerala,
Total plot area of the site is 703 m2 from which 232 m2 will be developed as greenbelt,
roject site is given in Figure 2-1.
Identification Latitude &
Longitude
22°46'12.52"N
72°20'12.08"E
1 22°46'13.19"N
72°20'12.02"E
2 22°46'12.90"N
72°20'12.66"E
3 22°46'11.87"N
72°20'12.10"E
4 22°46'12.14"N
72°20'11.47"E
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
4
Figure 2-1: Location of the Project Site
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
5
Table 2-1: Salient Features within 10 km Radius of project site
Sr.
No. Feature Description
1. GPS Co-ordinates 22°46'12.52"N
72°20'12.08"E
2. Mean Sea Level 23 m
3. Temperature Range 9-45 °C
4. Annual Rainfall 500-1000 m
5. Nearest Airport Ahmedabad airport 43.94 km in NE
6. Nearest Road NH-8A 1.48 km in W and SH-74 7.06 km in E
7. Nearest Railway Station Bavla railway station 7.46 km in NNE
8. Nearest City Bavla Town 6.35 km in NNE
9. Nearest River None within 10 km radius.
10. Seismic Zone Zone – III (Medium Risk Zone)
11. National Park and Sanctuary None within 10 km radius.
2.2 PROCESS DESCRIPTION
For detailed manufacturing process, chemical reactions, material balance and process flow diagram please refer
Annexure – 1.
2.3 RAW MATERIALS REQUIREMENT
Raw material will be purchased from local market and convenient mode of transportation is either road/
railways. raw material consumption is attached as Annexure – 2.
2.4 RESOURCE OPTIMIZATION / RECYCLING AND REUSE IN THE PROJECT
The materials will be packed in drums and stored in a very organized way, segregated as Solid and Liquid area
in ware house. Good house-keeping, good Manufacturing practices, best Environment control, safety and health
practices will be obtained. By adoption of continuous improvement in technology and processes the desired
reduction in process waste generation will be achieved. By proper and efficient handling of raw materials,
wastages of raw materials will be reduced.
2.5 AVAILABILITY OF WATER AND POWER
2.5.1 Water
The fresh water requirement for domestic and industrial activities is estimated 20.5 KLD, which will sourced
from GIDC, Kerala.
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
6
Table 2-2: Water Consumption and Wastewater Generation
Sr.
No Category
Water
Requirement
(KLD)
Wastewater
Generation
(KLD)
Wastewater Treatment
(A) Domestic 0.7 0.6 Septic tank/soak pit
(B) Industrial
1 Processing 10.3 21.1 High COD stream to CHWIF and
Low COD stream to ETP
2 Cooling Tower 1.5 0.3 To ETP
3 Boiler 5 1 To ETP
4 Washing 2 1.7 To ETP
(C) Green Belt 1 -- --
Total (A+B+C) 20.5 24.7
2.5.2 Power
Power requirement will be around 50 HP which will be sourced from Uttar Gujarat Vij Company Limited
(UGVCL). One DG set (80 kVA) will be installed as backup source of power and used only in case of power
failure.
2.6 WASTE MANAGEMENT/DISPOSAL
2.6.1 Water Environment
Industrial effluent (24.11 KLD) will be generated during operation phase of propose plant. There will be high
COD and low COD stream segregation at source. High COD stream (11 KLD) will be sent to CHWIF. Low
COD stream (12.68 KLD) will be treated in ETP of capacity 15 KLD having primary, secondary and tertiary
treatment units. Treated effluent (12.68 KLD) will further treated in single effect evaporate of capacity 15 KL to
achieve Zero Liquid Discharge. Sewage (0.6 KLD) will be treated in septic tank and soak pit system.
2.6.2 Air Environment
There will be flue gas emission expected from boiler of capacity 1000 kg/Hr. and D.G. set, while process
emission from reactor. Detail of flue and process emission is as under;
Table 2-3: Flue gas Emission
Stack
No.
Stack
Attached to Fuel Type
Fuel
Quantity
Stack
Height
(m)
Stack
Diameter
(m)
Air Pollution
Control System Permissible Limit
1. Boiler HSD 25 L/d 30 0.25 Adequate stack
height
SPM ≤ 150 mg/nm3
SO2 ≤ 100 ppm
NOX ≤ 50 ppm
2. D.G. SET Diesel 16 L/h 10 -- Adequate stack
height
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
7
Table 2-4: Process Emission
Sr.
No. Stack Attached To
Expected
Pollutant
Stack Height
(m)
Air Pollution Control
System Permissible Limit
1. Reactor HCl 20 Caustic Scrubber HCl ≤ 20 mg/Nm3
2.6.3 Solid/hazardous Waste
Following wastes will be generated at the end of manufacturing process or treatment process which will be
managed as per solid/hazardous waste management rule – 2016. All the wastes will be stored at designated area
having pucca floor, roof and leachate collection system.
Table 2-5: Waste Generation
Sr.
No Name of The Waste Category Quantity (MTPA)
Method of Storage and
Disposal
1. Process waste/residue 28.1 2.4 Collection, storage and
transport to TSDF site.
2. ETP Sludge 35.3 18 Collection, storage and
transport to TSDF site.
3. Used oil 5.1 30 L/annum
Collection, storage,
transportation, reuse/selling to
registered refiners.
4. Discarded Containers
/Barrels /Linear 33.1 600 Nos./ Annum
Collection, storage,
decontamination send to
authorized recycler.
5. Oily / Contaminated
Cotton waste 33.2 0.06
Collection, storage and
transport to TSDF site.
6. Spent Carbon 28.3 6 Collection, Storage and send
for Incineration.
7. Spent Solvent 28.6 120 Sent to distillation plant for
distillation
8. Date-expired products 28.5 So ever generated Incineration at common
facility
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
8
CHAPTER-3 SITE ANALYSIS
3.1 CONNECTIVITY
The unit is located in GIDC area which well connected to rest of the country through highways, railways and
airports. The details of the facility with distance from the unit is as under:
Sr.
No. Particular Description
Distance
(km) Direction
1. Nearest National Highway NH-8A
SH74
1.48
7.06
W
E
2. Nearest town Bavla 6.35 NNE
3. Nearest Airport Ahmedabad 43.94 NE
4. Nearest Railway station Bavla 7.46 NNE
3.2 COMMUNICATION
Proposed project site is within GIDC premises which is already well connected with telephone, telefax etc. all
the communications facilities are well developed in the area.
3.3 TOPOGRAPHY AND GEOGRAPHY OF THE STUDY AREA
It has been observed that the major area of study area is levelled plain to nearly level with small slopes. Over all
slope direction of the study area is noticed towards south to north.
The area forms part of North Gujarat Alluvial Plain with elevations ranging from 40 to 50 m MSL. The area is
under lain by post Miocene alluvium comprising sand, gravel, silt and clay. The alluvium is about 400 m thick
under lain by tertiary formation. The alluvium mainly consists of palaeo deltaic, fluvial and Aeolian sediments,
comprising alternate bands of fine to course grained sand, gravel and yellowish brownish sticky clay.
The soils found in the district are mostly of Black soil, Goradu soil, Kyari and Rocky soil. Medium Black Soils
are suitable for growing crops like bajri, jowar and cotton; all kinds of crops can grow in Goradu soil; varieties
of paddy such as Pankali, kamod, Jirasar, Sukhvel, Sutarsal and Basumati are grown on Kyari soil; and rocky
soils are fit for early maturing crops like cotton, Bajri, Jowar and Math.
3.4 CLIMATE OF THE STUDY AREA
The unit is located in Bavla Taluka of Ahmedbad district. The general agro-climatic zone of the study area is
Semi-arid to dry sub-humid. Period of March to May is one of the continuous rise in temperature. May is the
hottest month while January is the coldest month. Temperature range is 9°-45°C.
Winds are generally light with some strengthening in force in summer and in the south-west monsoon season.
During South west monsoon winds are generally SW to W. during end of monsoon NW winds also starts. Wind
direction is between NW & NE in morning; between SW & NW in afternoon in February & March. Rest of
summer wind direction is between SW & NW
The climate of the district is characterized by hot summer and general dryness except during the southwest
monsoon seasons. The year can be divided into four seasons. The period from March to May is the hot season
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
9
(summer) followed by southwest monsoon from June to September. October and November constitute the post-
monsoon or retreating monsoon season. The cold season (winter) starts from December and ends in February
The annual rainfall is received during SW monsoon season from June-September, with July being the highest
rainfall month. Average annual rainfall is 500 – 700 mm.
3.5 EXISTING LAND USE PATTERN
There is no Forest, National park; Wild life sanctuary within a radius of 10 km. The study area comprises of
• Industrial estates of Kerala GIDC; other industries.
• Residential areas of Bavla town and other small villages
• Small talav and canal from Vasna Barrage
• Cropped area
3.6 EXISTING SOCIAL STRUCTURE
Project site is located at Kerala, G.I.D.C. All the infrastructures are available within city like Schools, Colleges,
Hospitals & community facilities even nearby area of the project site is also developed.
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
10
CHAPTER-4 PLANNING BRIEF
4.1 PLANNING CONCEPT
The unit is located in Kerala GIDC which has different types of industries, such as Pharmaceutical, resins,
chemicals. The proponent is intending to manufacture Active Pharmaceutical Ingredients, the Active
Pharmaceutical Ingredient industry is the organ by which active pharmaceutical ingredients are manufactured
from raw materials through both chemical and physical means. Depending on the complexity of the molecule
required, synthesis of APIs might need multi-step complex chemistry utilizing a range of processing
technologies.
4.2 LAND USE PLANNING
The general Plant Layout has been planned considering production facilities, auxiliary and ancillary facilities
and plant utilities & services. Total plot area of the project is 703 m2. Land use shall be as build up area of
buildings, storage facility, roads, greenbelt, open land etc. Layout plant of proposed unit is given in figure 4-1
and the land use break-up is as under:
Sr. No Particular Land Area (m2)
1. Built up area 332
2. Green belt Area 232
3. Open/paved area 139
Total 703
4.3 AMENTIES / FACILITIES
Following facilities will be provided in the proposed unit:
• Adequate storage facility for chemicals, machinery spares and consumables
• Time and security offices
• Internal fire hydrants system
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
11
Figure 4-1: Plant Layout
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
12
CHAPTER-5 PROPOSED INFRASTRUCTURE
5.1 INDUSTRIAL AREA
The company has already acquired land area of 703 m2
in which company will expand their production
capacity.
5.2 GREEN BELT
The main objective of the green belt is to provide a barrier between the source of pollution and the surrounding
areas. The green belt helps to capture the fugitive emission and to attenuate the noise generated apart from
improving the aesthetics. Development of green belt and other forms of greenery shall also prevent soil erosion
and washing away of topsoil besides helping in stabilizing the functional ecosystem and further to make the
climate more conducive and to restore water balance. 232 m2 area across about 33% of the total area will
developed as green belt area with Lawn, plants and flowers spread. Green belt will be developed at plant
boundary, road side, around offices & buildings and Stretch of open land. The selection of tree species suitable
for plantation at the industry are governed by guiding factors as stated below:
• The trees should be tolerant to air pollutants present in the area
• The trees should be able to grow and thrive on soil of the area, be evergreen, inhabitant, having
minimum of leaf fall.
• The trees should be tall in peripheral curtain plantation and with large and spreading canopy in primary
and secondary attenuation zone.
• The trees should posses extensive foliar area to provide maximum impinging surface for continued
efficient adsorption and absorption of pollutants.
• The trees should be fast growing and indigenous and should maintain ecological, land and hydrological
balance of the region.
• It is also recommended to plant few trees, which are sensitive to air pollution, as air pollution indicator.
• It is also recommended to carry out extensive plantation within premises.
Keeping in view the climatic conditions, status of soils and vegetation types in and around the project area the
species shall be selected for proposed green belt development.
5.3 SOCIAL INFRASTRUCTURE
Expansion in existing infrastructure such as drinking water facility, canteen, proper sanitation, etc. will be
carried out as per requirement for the workers working in plant.
The Project proponent will contribute annually 2.5% of total profit towards CSR (Corporate Social
Responsibility) activity like following in nearby villages;
Education Facilities:- Facilities for village schools like game kits, drawing kits, table-chairs; school
construction (classroom/toilet/school boundary), ceiling fans or books for school library
Health Facilities:- to provide assistance to existing health facilities in Nearest Hospital, for improvement in
health facilities or services.
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
13
CHAPTER-6 REHABILITATION AND RESETTLEMENT (R & R) PLAN
The unit is located in GIDC area, which is already acquired for industrial purpose and there is no habitat. So the
project proposal does not involve any Rehabilitation & Resettlement.
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
14
CHAPTER-7 PROJECT SCHEDULE & COST ESTIMATES
7.1 TIME SCHEDULE FOR THE PROJECT
The implementation of the project will involve major activities like preparation of specification / drawings,
issue of tenders, receipt of quotations, scrutiny of tenders, placing of orders, civil & structural construction,
delivery & erection of equipment, test trial runs of various items of equipment and commissioning of the plant
& equipment and completion of the project will take about 6 months after the necessary clearances are
available, and the funding for the project has been tied up.
7.2 ESTIMATED PROJECT COST
The total project cost for the proposed project would be around Rs. 250 Lacs. Total capital cost of pollution
control measures will be Rs. 50 lacs & recurring cost per annum will be 25 Lacs.
Sr. No. Particulars Rs. In lacs
1 Land 60
2 Plant Machineries/Utilities 100
3 Building construction 40
4 Environmental Management System 50
Total 250
7.3 BUDGETORY PROVISIONS FOR EMP
Adequate budgetary provisions have been made by the management for execution of environmental
management plans. The details of capital and recurring (per annum) budget earmarked for pollution control /
monitoring equipment; operation and maintenance of pollution control facilities, for greenbelt development and
maintenance.
Sr.
No. Particulars Rs. In lacs
1. Capital Expenditure 50
2. Recurring expenditure on environmental management cell and on
pollution control systems per annum. 25
PRE-FEASIBILITY REPORT OF PROPOSE API MANUFACTURING UNIT BY SHREE HARIKRISHNA PHARMACEUTICALS
15
CHAPTER-8 ANALYSIS OF PROPOSAL
8.1 FINANCIAL AND SOCIAL BENEFITS
The total cost of the proposed project is estimated at about Rs. 2.5 crore. For the coming of this project
surrounding area will get developed due to this project and through the Corporate Social Responsibility (CSR)
activities, socio-economic status of the region will also get developed.
Annexure 1
Contents
Annexure-1 Manufacturing Process, chemical reaction and mass balance ......................... 2
1. Deflazacort ................................................................................................................... 2
2. Acebrophylline ............................................................................................................ 3
3. Thiocolchicoside .......................................................................................................... 4
4. Solifenacin Succinate ................................................................................................... 5
5. Anagliptin .................................................................................................................... 7
6. Atazanavir sulphate ..................................................................................................... 8
7. Esclicarbazepine Acetate ........................................................................................... 11
8. Febuxostat .................................................................................................................. 13
9. Flupirtine maleate ...................................................................................................... 14
10. Methylcobalamine ..................................................................................................... 16
11. Mirabegron ................................................................................................................ 17
12. Pidotimod ................................................................................................................... 18
13. Teneligliptin Hydrobromide Hydrate ........................................................................ 19
14. Valsartan .................................................................................................................... 21
15. Pirfenidone ................................................................................................................. 23
16. N-Boc Amino acid ..................................................................................................... 24
17. Fluconazole ............................................................................................................... 25
18. Lostaran Potassium .................................................................................................... 26
19. Clopidogril Sulphate .................................................................................................. 28
20. Sertraline HCl ............................................................................................................ 29
21. Oxcarbazepine ........................................................................................................... 30
22. Nebivolol ................................................................................................................... 31
23. Telmisartan ................................................................................................................ 32
24. Clomipramine HCl ..................................................................................................... 32
25. Bisoprolol .................................................................................................................. 33
26. Tadalafil ..................................................................................................................... 34
27. Ticagrelor ................................................................................................................... 36
28. Vardenafil Hydrochloride Trihydrate ........................................................................ 40
29. Atorvastatin Calcium ................................................................................................. 40
30. Rosuvastatin Calcium: ............................................................................................... 44
Annexure-2 Raw Materials consumption .......................................................................... 47
Annexure 2
ANNEXURE-1 MANUFACTURING PROCESS, CHEMICAL REACTION AND
MASS BALANCE
1. Deflazacort
Acetylation of KSM-1 in the presence of acetic anhydride and DMAP to yield deflazacort.
Product: Deflozacort (Material flow sheet):
Annexure 3
2. Acebrophylline
a. Manufacturing Process
Theophylline-7-acetic acid react with ambroxol base in toluene as a solvent to give acebrophylline.
b. Chemical Reaction
c. Flow Diagram
Annexure 4
3. Thiocolchicoside
a. Manufacturing Process
KSM-1 react with 1,2,3,4,6-penta-O-acetyl-beta-D-glucopyranose in acetonitrile in the presence of
borontrifluoride etherate and sodium hydroxide to yiled thiocolchicoside.
b. Chemical Reaction
c. Flow Diagram
Annexure 5
4. Solifenacin Succinate
a. Manufacturing Process
Stage-I: KSM-I on reaction with ethylchloroformate in presence of trietyhl amine in toluene gives
intermediate stage-IA which on reaction with KSM-II in presence of sodium ethoxide in toluene gives
intermediate stage-IB which on reaction with succinic acid in acetone gives stage-I
Stage-II: Stage-I on treatment with isopropyl alcohol and successive workup gives stage-II
(Solifenacin Succinate)
b. Chemical Reaction
NH
(S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline(KSM-I)
N O
O
1) R-(-)-3-quinuclidinol (KSM-II)Sodium ethoxide solution,Toluene
1) Succinic acid, Acetone
Stage-1A
N O
ON
Stage-1B
Ethylchloroformate, TEA
N O
ON
COOH
COOH
Stage-I
IPA
N O
ON
COOH
COOH
Stage-II, Solifenacin Succinate
Annexure 6
c. Flow Diagram
Annexure 7
5. Anagliptin
a. Manufacturing Process
KSM-I react with KSM-II in the presence of EDC HCl, HOBT H2O, and potassium carbonate in MDC to give
anagliptin.
b. Chemical Reaction
c. Flow Diagram
Annexure 8
6. Atazanavir sulphate
a. Manufacturing Process
KSM-I react with KSM-II in IPA to give stage-I then deprotection of Boc group carried out using conc. HCl
followed by reaction with leucine ester in the presence of EDC HCl, HOBt in MDC to give stage-II. Atazanavir
sulphate was prepared by using sulfuric acid in methanol and acetone.
b. Chemical Reaction
Annexure 9
c. Flow Diagram
Annexure 10
Annexure 11
7. Esclicarbazepine Acetate
a. Manufacturing Process
Oxcarbazepine reacted with Catalyst, Catalyst-1, Catalyst-2 in the presence of IPA and
triethanolamine buffer solution, filtered & dried to give stage-1. Stage-1 reacted with acetic
anhydride, DMAP in the presence of MDC to give Esclicarbazepine acetate.
b. Chemical Reaction
c. Flow Diagram
Annexure 12
Annexure 13
8. Febuxostat
a. Manufacturing Process
Hydrolyzed the KSM-1 by using 1N NaOH solution in the presence of IPA and then acidify by using
1N HCl to give Febuxostat.
b. Chemical Reaction
c. Flow Diagram
Annexure 14
9. Flupirtine maleate
a. Manufacturing Process
Condensation of KSM-I and KSM-II in the presence of sodium carbonate to give Stage-I. Stage-I
reacted with Raney Ni and Hydrazine hydrate in the presence of IPA than reacted with ECF and
Maleic acid to give Flupirtine maleate.
b. Chemical Reaction
c. Flow Diagram
Annexure 15
Annexure 16
10. Methylcobalamine
a. Manufacturing Process
KSM-I react with trimethylsulfoxonium bromide in the presence of cobalt chloride, sodium
borohydride in 2-butanone to give Methylcobalamine.
b. Chemical Reaction
c. Flow Diagram
Annexure 17
11. Mirabegron
a. Manufacturing Process
Condensation of KSM-I and KSM-II by using DEC in the presence of process water and conc. HCl,
basify it by using liq. NH3 to give mirabegron.
b. Chemical Reaction
c. Flow Diagram
Annexure 18
12. Pidotimod
a. Manufacturing Process
Condensation of KSM-1and KSM-2 by using DCC in the presence of MDC to give Int-1 which was
then treated with sodium hydroxide and conc. HCl to give Pidotimod crude. Purified it by using IPA:
WATER solution filtered & dried to give pidotimod.
b. Chemical Reaction
c. Flow Diagram
Annexure 19
13. Teneligliptin Hydrobromide Hydrate
a. Manufacturing Process
Condensation of KSM-I and KSM-II by using STAB in the presence of MDC to give stage-I which
was then treated with MSA to give teneligliptin base (Stage-II). Reaction of stage-II with HBr in
Dysol as solvent to give teneligliptin hydro bromide hydrate.
b. Chemical Reaction
Annexure 20
c. Flow Diagram
Annexure 21
14. Valsartan
a. Manufacturing Process
Hydrochloride salt of KSM-I was broken by using NaHCO3 solution and then reacted with valeryl chloride in
the presence of DIPEA as a base to give Stage-I. Stage-I then reacted with sodium azide and tributyl tin chloride
in toluene to give Stage-II. Hydrolysis of Stage-II was carried out using NaOH solution to give Valsartan.
b. Chemical Reaction
Annexure 22
c. Flow Diagram
Annexure 23
15. Pirfenidone
a. Manufacturing Process
KSM-I was reacted with sulfuric acid and sodium nitrite in water to give Stage-I which was then
reacted with bromo benzene in the presence of potassium carbonate and copper(II)oxide in NMP as
solvent to give pirfenidone.
b. Chemical Reaction
c. Flow Diagram
Annexure 24
16. N-Boc Amino acid
a. Manufacturing Process
KSM-I was reacted with t-Boc anhydride in the presence of sodium hydroxide in water to give Stage-I
to give N-Boc Amino acid.
b. Chemical Reaction
c. Flow Diagram
Annexure 25
17. Fluconazole
a. Manufacturing Process
Epoxi decompounds intermediate &1, 2,4Triazolearetreated in presence of potassium carbonate. Once
reaction is over treated with ethylacetate, purified from IPA, filtered & dried to give Fluconazole.
b. Chemical Reaction
c.
c. Flow Diagram
Annexure 26
18. Lostaran Potassium
a. Manufacturing Process
2-Butyl-4chloro-5hydroxymethylimidazole reacted with4-bromomethyl-2 cyanobiphenyl & Na
Methoxide. Further treated with sodiumazide & NH4 Clinpresence of DMF. The mass is crystallized
from methanol to give lostaran potassium.
b. Chemical Reaction
Annexure 27
c. Flow Diagram
Annexure 28
19. Clopidogril Sulphate
a. Manufacturing Process
AminoEster(VIII)(+)-10-Camphor sulphonic acid reacted with Formic acid & Formaldehyde. The
mass is treated with Sulphuric acid, IPA+Water. The crude obtained is crystallized using water +
Methanol, filtered, and dried to give Clopidogril Sulphate.
b. Chemical Reaction
c. Flow Diagram
Annexure 29
20. Sertraline HCl
a. Manufacturing Process
4- (3, 4-Dichlorophenyl)-3,4-dihydro-1(2H)-naphthalene, Methylamine Lewis acid & Hydrogen; D(-)
Mandelic acid with Conc. HCl. The crystallized from Methanol + Water, filtered & dried to give
Steraline HCL.
b. Chemical Reaction
c. Flow Diagram
Annexure 30
21. Oxcarbazepine
a. Manufacturing Process
5H-Dibenz [b,f]azepine-5-carbonitrile;Sodium nitrite treated in presence of Acetic acid & Iron Boron
Trifluoride is added. The mass is filtered to give crude product, crystallized from IPA, filtered & dried
to give Oxcarbazepine.
b. Chemical Reaction
c. Flow Diagram
Annexure 31
22. Nebivolol
a. Manufacturing Process
Benzopyran-2-Carboxaldehyde Derivative treated with Trimethyl sulfoxoniumiodide. In presence of
Potassium hydroxide & Water. The mass is further treated with Benzyl amine &Toluene, Ammonium
formate using Pd/Catalyst. The mass is crystallized from Methanol, filtered &dried to give Nebivolol.
b. Chemical Reaction
c. Flow Diagram
Annexure 32
23. Telmisartan
a. Manufacturing Process
Charge Benzaimidazole compound, N-methyl-O-phenylenediamine, toluene, Poly phosphoric Acid
heat and reflux distilled out Toluene. Add Toluene and Bromoester cool & filters drying RCVD to get
Telmisartan.
b. Chemical Reaction
c. Flow Diagram
24. Clomipramine HCl
a. Manufacturing Process
Charge ChloroIminodibenzyl Dimethylaminopropylchloride, Toluene, KOH heat and reflux distilled
out Toluene. Add DMWater, Acetone, HCl cool & filters drying RCVD to get Clomipramine HCl.
Annexure 33
b. Chemical Reaction
c. Flow Diagram
25. Bisoprolol
a. Manufacturing Process
Charge Isopropylamino propanol, Isopropylethoxy-p-tolyl compound, IPA, KOH flakes, DM Water
heat and reflux distilled out IPA. Add DMwater Acetone, Fumaric Acid cool & filters drying RCVD
to get Bisoprolol.
Annexure 34
b. Chemical Reaction
c. Flow Diagram
26. Tadalafil
a. Manufacturing Process
Stage-I: KSM-I on reaction with KSM-II in IPA gives Stage-I
Stage-II: Stage-I on reaction with chloroacetyl chloride in presence of sodium bicarbonate in MDC
gives stage-II.
Stage-III: Stage-II on reaction with mono methylamine in methanol gives Stage-III (Tadalafil) on
successive workup
Annexure 35
b. Chemical Reaction
c. Flow Diagram
Annexure 36
27. Ticagrelor
a. Manufacturing Process
Stage –I: KSM-I on reaction with KSM-II in DMSO and Toluene in presence of triethyl amine gives
intermediate stage-IA which on deportation with hydrochloric acid in ethanol and toluene gives stage-
I
Stage-II: Stage-I on reaction with sodium nitrite in acetic acid and toluene gives intermediate stage-II
which on reaction with KSM-III in toluene in presence of triethyl amine gives stage-II
Stage-III: Stage-II on reduction with sodium borohydride in diglyme gives ticagrelor on successive
workup
Annexure 37
b. Chemical Reaction
Annexure 38
c. Flow Diagram
Annexure 39
Annexure 40
28. Vardenafil Hydrochloride Trihydrate
a. Manufacturing Process
Stage-I:
KSM-I on reaction with chlorosulfonic acid gives intermediate stage-IA which on reaction with KSM-
II in MDC gives intermediate stage-I.
Stage-II
Stage-I on treatment with conc. Hydrochloric acid in isopropyl alcohol gives stage-II (Vardenafil
Hydrochloride Trihydrate)
b. Chemical Reaction
29. Atorvastatin Calcium
c. Manufacturing Process
KSM-I hydrogenated with Raney Ni to give stage-I which is react with KSM-II in the presence of
pivalic acid and cyclohexane to give stage-II which on Deprotection with hydrochloric acid and
hydrolysis with NaOH to give atorvastatin acid and further to form calcium salt of atorvastatin with
calcium chloride.
Annexure 41
d. Chemical Reaction
Annexure 42
e. Flow Diagram
Annexure 43
f. Flow Diagram
Annexure 44
30. Rosuvastatin Calcium:
a. Manufacturing Process
KSM-I hydrolyzed by sodium hydroxide solution to produce Int-1 followed by oxidation with sodium
hypochlorite and TEMPO to give Int-2 which is react with KSM-II in the presence of potassium
carbonate and toluene to give stage-II which on Deprotection with hydrochloric acid and hydrolysis
with NaOH to give rosuvastatin acid and further to form calcium salt of rosuvastatin with calcium
chloride.
b. Chemical Reaction
c. Flow Diagram
Annexure 45
Annexure 46
Annexure 47
ANNEXURE-2 RAW MATERIALS CONSUMPTION
No. Name of Raw Material Consumption in MTPM
1 KSM-I 115.5
2 Raaney Ni 0.4
3 Liq. Ammonia 6.5
4 IPA 748.3
5 Hyflow 1.3
6 Cyclohexane 5.9
7 KSM-II 67.7
8 pivalic Acid 0.0
9 water 1988.2
10 5 % Sodium Bicarbonate 1.2
11 Methanol 410.1
12 2% Dil. HCl 7.1
13 10% NaOH solution 0.9
14 MTBE 2.5
15 Calcium Chloride Dihydrate 0.1
16 Toluene 664.1
17 ethyl acetate 531.7
18 acetic Anhydride 7.6
19 DMAP 0.3
20 Aq. Buffer 77.3
21 Acetonitrile 105.6
22 1,1,3,3-tetramethylguanidine 5.3
23 borontriflouride etherate 14.4
24 Sodium Hydroxide solution 41.7
25 Sodium thiosulphite solution 27.8
26 Sodium bicarbonate solution 133.0
27 Sodium Chloride Solution 117.7
28 Diethylamine 17.8
29 potassium carbonate 21.7
30 MDC 516.2
31 Potassium Bromide 0.0
32 TEMPO 0.0
33 Sodium Hypochlorite 0.6
34 Sodium Thiosulphate 0.0
35 potassium chloride 0.1
36 DMSO 5.1
37 EDC HCl 10.1
38 HOBT water 1.3
39 35% K2CO3 Solution 57.2
Annexure 48
No. Name of Raw Material Consumption in MTPM
40 Activate Carbon 2.3
41 celite 4.1
42 EToAC 7.9
43 conc.Hcl 81.2
44 leucine ester 9.2
45 DIPA 19.0
46 NaHCO3 151.6
47 DNS solution 103.9
48 Conc. H2SO4 19.1
49 Acetone 190.1
50 oxcarbazepine 9.5
51 triethanol amine buffer solution 38.1
52 Catalyst 0.1
53 10% Na2CO3 Solution 23.6
54 0.35%dil.HCl Sol. 22.4
55 1N NaOH Solution 43.6
56 1N HCl Solution 17.8
57 Sodium Carbonate 7.3
58 Hydrazine hydrate 6.8
59 ECF 3.4
60 Maleic Acid 3.6
61 Aq. IPA 25.2
62 Cobalt chloride hexahydrate 0.8
63 2-Butanone 8.6
64 Ion Exchanged water 206.9
65 Sodium Borohydride 4.6
66 Trimethyl Sulfonium Bromide 4.4
67 DEC 6.3
68 DCC 9.6
69 NaOH 6.2
70 DCM 26.3
71 STAB 10.5
72 MSA 7.1
73 DYSOL 74.7
74 Hydrobromic Acid Solution 6.3
75 Sodium sulphate 2.1
76 DIPEA 5.4
77 Vleryl Chloride 4.2
78 Sodium bicarbonate 3.5
79 Sodium Azide 7.2
80 Trybutyl Tin Chloride 18.4
81 KOH 16.5
82 Sodium Nitrite 11.8
Annexure 49
No. Name of Raw Material Consumption in MTPM
83 NMP 12.5
84 Bromo Benzene 13.5
85 Copper(II) Oxide 0.5
86 Sodium Chloride 21.2
87 Amino Acid 7.7
88 48% NaOH Solution 2.3
89 t-BOC Anhydride 17.6
90 EpoxideIntermediate 12.0
91 1,2,4-Triazole 14.3
92 Dimethyl Formamide DMF 43.2
93 Acetic Acid 29.7
94 2-Butyl-4chloro-5 hydroxy methylimidazole 19.5
95 4-bromomethyl-2- cyanobiphenyl 10.1
96 Sodium Methoxide 33.6
97 Ammonium Chloride 2.1
98 Methanol +m Water 39.9
99 Aminoester (VIII)
(+)-10-Camphorsulphoic acid
28.2
100 Formic Acid 18.5
101 Formaldehyde 3.3
102 4-(3, 4-Dichlorophenyl)-3,4-dihydro-1(2H)-
naphthalene
14.2
103 Methylamine 3.7
104 Lewis Acid 2.9
105 Hydrogen 1.6
106 D(-)Mandelicacid 8.5
107 5H-Dibenz[b,f]azepine-5- carbonitrile 13.5
108 Iron 0.8
109 BoronTrifluoride 3.5
110 Benzopyran-2- Carboxaldehyde Derivative 14.0
111 Trimethyl sulfoxonium Iodide 11.5
112 Benzyl Amine 4.0
113 Ammonium Formate 6.0
114 pd/c 0.1
115 Benzaimidazolecompound 14.3
116 NMethyl-O- Phenylenediamine 12.1
117 Poly Phosphoric Acid 35.7
118 Bromo ester 8.6
119 ChloroIminodibenzyl 13.3
120 Dimethylaminopropyl chloride 11.3
121 Isopropylaminopropanol 0.6
122 Isopropylethoxy-p- tolylcompound 12.5
123 KOH Flake 0.3
Annexure 50
No. Name of Raw Material Consumption in MTPM
124 Fumaric Acid 5.0
125 Triethyl Amine 4.1
126 Ethyl Chloroformate 4.3
127 Succinic Acid 4.2
128 Chlorosulfonic Acid 0.6
129 Chloroacetyl chloride 8.8
130 40% Methyl amine solution in water 50.0
131 Ethanol 4.3
132 KHCO3 0.4
133 Diglyme 1.6
Annexure 51